The global anti oral mucositis drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing amount of cancer diseases and treatments related to it this factor will lead to the growth of the market during the forecast period. Oral mucositis is a complication that happens after cancer treatment such as radiotherapy and chemotherapy. The chemotherapy affects the inner lining epithelial cells and destroys the gastrointestinal tract due to which mucosal cells are wide open and can catch the infection. Due to this factor, the demand for the drug will grow during the forecast period.
Along with that, the rising geriatric population having cancer is also increasing which will likely drive the market. Oral-mucositis is diagnosed with brutal oral pain and ulcers due to which there is a higher need for a quick and efficient way to cure the pain that is fueling the demand for these drugs. Recently, in 2020, US FDA granted permission for the fast track launch of SGX942 (Soligenix, Inc.) for patients suffering from oral mucositis in combination with neck and head cancer. In 2020, BMG pharma added Gelx for the treatment of the disease. Some of the key players in the global oral mucositis drug market include Amang Pharmaceuticals, Cellceutix, Izun Pharma, Himalaya, Oragenics, Kinnear Pharmaceuticals, Shoreline Pharmaceutical, and many others.
Market Coverage
o By Type
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Anti-Oral Mucositis Drug Market by Segments
o By Type
o By End-User
Global Anti-Oral Mucositis Drug Market by Region
North America
Europe
Asia-Pacific
Rest of the World
REQUEST FOR TABLE
OF CONTENT